Brief: Oncosec Says First Subjects Dosed In Phase 1 Trial Of Corvax12
27/01/2021 14:31
Jan 27 (Reuters) - OncoSec Medical Inc ONCS.O :
* ONCOSEC ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 TRIAL OF
CORVAX12, ONCOSEC'S COVID-19 VACCINE CANDIDATE COMBINING
INTERLEUKIN-12 (IL-12) WITH AN ENHANCED SARS-COV-2 SPIKE PROTEIN
* ONCOSEC MEDICAL - PRELIMINARY PRECLINICAL DATA
DEMONSTRATED
CORVAX12 ADMINISTERED INTO TUMOR TISSUE NOT ONLY YIELDS A
PRODUCTIVE ANTI-VIRAL RESPONSE
Source text for Eikon: ID:nPnK43lPa
Further company coverage: ONCS.O
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on OncoSec Medical Incorporated
See all newsBrief: OncoSec Medical Inc On June 15 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Domino's, Aldeyra, MicroVision
Brief: OncoSec Medical Files Voluntary Petition For Relief Under Provisions Of Chapter 7 Of Title 11 Of United States Code
Brief: OncoSec Medical Terminates George Chi For Cause As Employee, CFO
Brief: Oncosec Medical Receives Non Compliance Notice From Nasdaq